BCDA
Price
$2.35
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
INO
Price
$4.95
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
Ad is loading...

BCDA vs INO

Header iconBCDA vs INO Comparison
Open Charts BCDA vs INOBanner chart's image
BioCardia
Price$2.35
Change-$0.00 (-0.00%)
Volume$56.89K
CapitalizationN/A
Inovio Pharmaceuticals
Price$4.95
Change-$0.00 (-0.00%)
Volume$612.15K
CapitalizationN/A
BCDA vs INO Comparison Chart
Loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BCDA vs. INO commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCDA is a StrongSell and INO is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (BCDA: $2.35 vs. INO: $4.96)
Brand notoriety: BCDA: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCDA: 45% vs. INO: 197%
Market capitalization -- BCDA: $8.23M vs. INO: $133.72M
BCDA [@Biotechnology] is valued at $8.23M. INO’s [@Biotechnology] market capitalization is $133.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCDA’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • BCDA’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than BCDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCDA’s TA Score shows that 4 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • BCDA’s TA Score: 4 bullish, 4 bearish.
  • INO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BCDA and INO are a good buy in the short-term.

Price Growth

BCDA (@Biotechnology) experienced а -2.08% price change this week, while INO (@Biotechnology) price change was -12.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.83%. For the same industry, the average monthly price growth was +3.51%, and the average quarterly price growth was +6.16%.

Reported Earning Dates

BCDA is expected to report earnings on Aug 13, 2024.

INO is expected to report earnings on May 08, 2024.

Industries' Descriptions

@Biotechnology (-1.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INO($124M) has a higher market cap than BCDA($7.06M). INO YTD gains are higher at: -18.954 vs. BCDA (-76.413). BCDA has higher annual earnings (EBITDA): -8.53M vs. INO (-118.07M). INO has more cash in the bank: 110M vs. BCDA (1.42M). BCDA has less debt than INO: BCDA (1.14M) vs INO (13M). INO has higher revenues than BCDA: INO (592K) vs BCDA (428K).
BCDAINOBCDA / INO
Capitalization7.06M124M6%
EBITDA-8.53M-118.07M7%
Gain YTD-76.413-18.954403%
P/E RatioN/AN/A-
Revenue428K592K72%
Total Cash1.42M110M1%
Total Debt1.14M13M9%
FUNDAMENTALS RATINGS
BCDA vs INO: Fundamental Ratings
BCDA
INO
OUTLOOK RATING
1..100
684
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
8765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCDA's Valuation (55) in the null industry is in the same range as INO (56) in the Medical Specialties industry. This means that BCDA’s stock grew similarly to INO’s over the last 12 months.

BCDA's Profit vs Risk Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that BCDA’s stock grew similarly to INO’s over the last 12 months.

INO's SMR Rating (97) in the Medical Specialties industry is in the same range as BCDA (100) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

INO's Price Growth Rating (65) in the Medical Specialties industry is in the same range as BCDA (87) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as BCDA (100) in the null industry. This means that INO’s stock grew similarly to BCDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCDAINO
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
BCDA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFMLX39.300.29
+0.74%
DF Dent Midcap Growth Institutional Plus
IEYAX9.370.06
+0.64%
Delaware Climate Solutions A
TOTTX12.18-0.02
-0.16%
Transamerica Mid Cap Value Opps I3
TRWTX21.11-0.19
-0.89%
Transamerica International Equity I3
OGNRF0.95-0.03
-2.59%
Orogen Royalties Inc.

BCDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCDA has been closely correlated with SMMT. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BCDA jumps, then SMMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCDA
1D Price
Change %
BCDA100%
-2.08%
SMMT - BCDA
68%
Closely correlated
-6.21%
MDGL - BCDA
29%
Poorly correlated
-7.05%
INO - BCDA
28%
Poorly correlated
-3.69%
KOD - BCDA
28%
Poorly correlated
+8.27%
KPTI - BCDA
28%
Poorly correlated
-3.52%
More

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-3.69%
AXON - INO
53%
Loosely correlated
+1.05%
ARRY - INO
52%
Loosely correlated
+1.97%
ONCO - INO
50%
Loosely correlated
-2.27%
ALNY - INO
42%
Loosely correlated
-1.67%
BTAI - INO
39%
Loosely correlated
-6.92%
More